Stress gastritis revisited

Surg Clin North Am. 1991 Aug;71(4):791-810. doi: 10.1016/s0039-6109(16)45486-1.

Abstract

In current ICU populations, overt bleeding from stress gastritis occurs in 10% to 20% of patients. Bleeding rates may be reduced to about 3% in patients receiving prophylactic therapy. Although patients with bleeding have higher mortality rates than other critically ill patients, it is not clear that the mortality rate is improved with prophylactic therapy, as most patients die from their underlying disease. As new complications of prophylactic therapy are identified, better definitions of the population at risk to develop complications of stress gastritis will be necessary to select those patients who will benefit most from prophylactic therapy.

Publication types

  • Review

MeSH terms

  • Antacids / adverse effects
  • Antacids / therapeutic use
  • Bicarbonates
  • Cimetidine / adverse effects
  • Cimetidine / therapeutic use
  • Epithelium / physiology
  • Gastric Mucosa / blood supply
  • Gastric Mucosa / physiopathology
  • Gastritis* / complications
  • Gastritis* / diagnosis
  • Gastritis* / physiopathology
  • Gastritis* / prevention & control
  • Gastrointestinal Hemorrhage / drug therapy
  • Gastrointestinal Hemorrhage / etiology
  • Histamine H2 Antagonists / therapeutic use
  • Humans
  • Intercellular Junctions / physiology
  • Mucus / physiology
  • Prostaglandins / therapeutic use
  • Stress, Physiological / complications*
  • Stress, Physiological / physiopathology
  • Sucralfate / therapeutic use

Substances

  • Antacids
  • Bicarbonates
  • Histamine H2 Antagonists
  • Prostaglandins
  • Sucralfate
  • Cimetidine